| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | SCHEDULE 13D/A |
| 12 Nov 2026 |
Form 4: Juniper Investment Company, Llc, 10% owner and 2 others
Bought 675,000 shares ($5M) · Bought 14,803 shares ($104K) |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net ... |
| 04 Nov 2026 |
Form 4: Fisher Patrick, President, Global Limb Recon
Sold 150 shares ($1.36K) |
| 05 Oct 2026 |
Form 4: Fisher Patrick, President, Global Limb Recon
Sold 150 shares ($1.42K) |
| 23 Sep 2026 |
Form 4/A: Juniper Investment Company, Llc, 10% owner and 2 others
Bought 120,000 shares ($1.05M) · Bought 190,000 shares ($1.68M) |
| 22 Sep 2026 |
Form 4: Juniper Investment Company, Llc, 10% owner and 2 others
Acquired 120,000 shares (Open Market Sale) ($1.05M) · Acquired 190,000 shares (Open Market Sale) ($1.68M) |
| 03 Sep 2026 |
Form 4: Fisher Patrick, President, Global Limb Recon
Sold 150 shares ($1.41K) |
| 01 Sep 2026 | 144 |
| 20 Aug 2026 |
Form 4: Fisher Patrick, President, Global Limb Recon
Sold 1,295 shares ($13.1K) |
| 18 Aug 2026 |
Form 4: Juniper Investment Company, Llc, 10% owner and 2 others
Acquired 19,500 shares (Open Market Sale) ($202K) · Acquired 20,000 shares (Open Market Sale) ($200K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | S-8 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
LEWISVILLE, Texas — August 5, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress toward a more foc... |
| 02 Jul 2026 |
8-K: Regulation FD Disclosure
On April 16, 2026, the U.S. Food and Drug Administration (“FDA”) issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices. Following that order, the Centers for Medicare & Medicaid Servic... |
| 22 Jun 2026 |
Form 4: McPherron Aviva, Pres, Global Ops & Qual
Sold 3,670 shares ($34.4K) |
Loading...